Elon Musk Company Neuralink get approval from the Food and Drug Administration (FDA) to conduct its first human clinical study. Neuralink is a neurotechnology company that Musk co-founded, and the company aims to develop brain implants that could assist paralyzed individuals in regaining mobility and dealing with other neurological conditions.
In a tweet, Neuralink expresses his excitement about receiving permission from the FDA to launch their first clinical study. Elon Musk is waiting and expecting this approval from 2019 and previously predicted Neuralink’s success. However, Neuralink faced a setback in early 2022 when the FDA initially rejected its human clinical study application. Since then, Neuralink has been addressing the FDA’s concerns regarding implant safety.
Neuralink’s Tweet emphasized the collaborative efforts between the team and the FDA, acknowledging it as an essential initial step toward utilizing their technology to assist numerous individuals in the future.
The company’s recruitment for clinical trials has not yet been initiated; they will be providing information regarding this process soon. Elon Musk launched Neuralink in 2016 with the vision of developing a powerful brain chip that enables electronic devices to be controlled by brains. The ultimate goal of this project is to help a person with paralysis regain their motor function by combining artificial intelligence and human abilities through the brain chip. According to Musk, it also contributes to the treatment of brain diseases such as Parkinson’s, dementia, and Alzheimer’s.